Vascular Solutions and ITGI Medical announce a “cooperation agreement” in pursuit of FDA Humanitarian Device Exemption for ITGI’s Aneugraft Dx coronary covered stent.

Stent makers Vascular Solutions (NSDQ:VASC) and ITGI Medical Ltd. (TASE:ITGI) joined forces this week in pursuit of regulatory and commercial progress for ITGI’s Aneugraft Dx coronary covered stent.
Under the terms of the agreement Vascular Solutions will become the exclusive U.S. distributor for the Aneugraft Dx system when it lands market approval, and the companies are sharing development costs. The project is slated to begin in Q1 2014 and should take 2-3.5 years, the companies said.